Combination of anti-human CD39 antibody, anti-human PD-1 antibody and chemotherapy in gastric cancer

Through a combination therapy of CD39 antibody, PD-1 antibody, FOLFOX or CAPOX, it solves the problem of limited effectiveness of existing treatment methods, significantly improves survival and response rate, and enhances immune response .

CN119013304APending Publication Date: 2024-11-22TRISHULA THERAPEUTICS INC +2
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380025371.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-07
Filing Date
2023-03-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing gastric cancer treatment methods have limited effect on patients with advanced gastric cancer, especially those with HER2-negative patients. The response rate and survival improvement of chemotherapy are limited, and the response rate and durability of anti-PD-1 agents alone are insufficient, which requires a synergistic strategy. To improve the therapeutic effect.

Method used

Combination therapy of CD39 antibody, PD-1 antibody, FOLFOX or CAPOX is used to treat gastric cancer patients by targeting the CD39 and PD-1 pathways and combining chemotherapy.

Benefits of technology

It significantly improved the survival and progression-free survival of gastric cancer patients, increased the tumor response rate, and enhanced the immune response, especially in patients with HER2-negative gastric cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013304A_ABST
    Figure CN119013304A_ABST
Patent Text Reader

Abstract

Provided herein are administration and combination therapies using a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPOX in gastric cancer. The immune checkpoint inhibitor has thoroughly changed the cancer treatment normal form. These agents modulate the tumor microenvironment or other aspects of the immune system to overcome the immunosuppression of the host immune system caused by the tumor. The anti-PD-1 / programmed cell death ligand-1 (PD-L1) agents target the immunosuppressive pathway and have been shown to be beneficial in many tumor types.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Provided herein are administration and combination therapies using CD39 antibodies, PD-1 antibodies, and FOLFOX or CAPOX in gastric cancer. Background Art

[0002] Immune checkpoint inhibitors have revolutionized the cancer treatment paradigm. These agents modulate the tumor microenvironment or other aspects of the immune system to overcome tumor-induced immunosuppression of the host immune system. Anti-PD-1 / programmed cell death ligand-1 (PD-L1) agents target immunosuppressive pathways and have been shown to be beneficial in many tumor types.

[0003] Research over the past decade has uncovered several new immune regulatory pathways. Among them, the adenosine pathway has become one of the most promising targets in immuno-oncology. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment. The adenosine is primarily produced extracellularly by sequential dephosphorylation of adenosine triphosphate (ATP) by ectonucleotidases CD39 and CD73.

[0004] Both CD39 and CD73 are reported to be elevated in hematological neoplasias such as leukemias and lymphomas as well as in a variety of solid tumor types. In solid tumors, ATP is released in large quantities in the extracellular space, reaching concentrations more than a thousand times higher than in healthy tissues. This is mainly due to cell death in the tumor core, metabolic or hypoxic stress, and pro-inflammatory signals that stimulate active export of ATP.

[0005] Chemotherapy-induced immunogenic cell death is mediated in part by the release of extracellular ATP. Tumors are adept at converting ATP to adenosine via CD39 and CD73 on malignant cells, regulatory immune cells, and the vasculature. These ectonucleases regulate purinergic signaling by primarily scavenging proinflammatory ATP and generating immunosuppressive adenosine.

[0006] CD39 is the major rate-limiting enzyme in the adenosine cascade and has an important role in tumor progression. Blockade of CD39 enzymatic activity can stimulate anti-tumor immunity across various tumors by preventing the production of immunosuppressive adenosine and promoting the accumulation of ATP in the tumor microenvironment. Therefore, CD39 can be viewed as an immune switch that shifts ATP-driven pro-inflammatory immune cell activity toward an anti-inflammatory state mediated by adenosine and is therefore a unique therapeutic target for oncology indications.

[0007] Gastroesophageal cancer (GEC) is the fifth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide. In 2018, more than 1.6 million new GEC cases and approximately 1.3 million related deaths were estimated to occur. In the United States, it is estimated that 45,000 new GEC cases will be diagnosed in 2019, and there will be approximately 27,000 GEC-related deaths. GEC remains difficult to cure because most patients present with advanced disease. The prognosis for advanced GEC is poor, with an estimated 5-year overall survival (OS) rate of approximately 5% to 20%.

[0008] Treatment of advanced / metastatic GEC is based on human epidermal growth factor receptor 2 (HER2) status. However, unlike breast cancer, the prognostic significance of HER2 status in GEC is unclear. Although further studies are needed to evaluate the prognostic significance of HER2 status in GEC, the addition of HER2 monoclonal antibodies to chemotherapy regimens has been shown to be a promising treatment option for patients with HER2-positive metastatic disease, which accounts for 12% to 23% of GEC.

[0009] For patients with HER2-negative GEC, chemotherapy is the standard first-line treatment for advanced disease. Currently, a fluoropyrimidine (fluorouracil or capecitabine) in combination with a platinum (oxaliplatin or cisplatin) is the mainstay of chemotherapy.

[0010] A recent phase 3 trial compared treatment with fluorouracil plus cisplatin versus fluorouracil plus oxaliplatin (FOLFOX) in 220 previously untreated patients with advanced gastric adenocarcinoma or esophagogastric junction cancer. Results showed that FOLFOX was associated with significantly reduced toxicity and a trend toward improved median progression-free survival (PFS) compared with fluorouracil plus cisplatin (5.8 months vs. 3.9 months; p=0.77). FOLFOX produced superior response rates (41.3% vs. 16.7%, respectively; p=0.12), time to treatment failure (5.4 months vs. 2.3 months; p<0.001), PFS (6.0 months vs. 3.1 months; p=0.029), and OS (13.9 months vs. 7.2 months) compared with fluorouracil plus cisplatin in patients aged >65 years.

[0011] Anti-PD-1 agents are also being developed as first-line treatments for GEC. On April 16, 2021, the US Food and Drug Administration approved PD-1 antibodies in combination with select types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. First-line treatment with PD-1 antibodies and chemotherapy showed a statistically significant improvement in OS compared with chemotherapy alone in previously untreated patients with PD-L1-positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. This study showed a statistically significant improvement in OS and PFS in patients with a PD-L1 combined positive score (CPS) ≥5.

[0012] Although impressive and durable responses were observed in a subset of patients treated with anti-PD-1 agents, response rates were rarely >50%, and responses were transient for most patients. Therefore, synergistic strategies may be beneficial for patients. Co-expression of PD-1 and CD39 is highly prevalent on tumor-infiltrating lymphocytes and marks exhausted effector T cell subsets in a variety of tumor types. Chemotherapy remains a key treatment option for many cancer patients, and it is conventionally believed that the chemotherapy directly kills tumor cells through their cytotoxic effects and triggers tumor cell death in a non-immunogenic manner.

[0013] What is needed is a combination of therapies. Summary of the invention

[0014] Disclosed herein are administration and combination therapies using CD39 antibodies, PD-1 antibodies, and FOLFOX or CAPOX.

[0015] A first aspect provides a method for treating a subject suffering from gastric cancer, the method comprising the step of administering to the subject a pharmaceutical composition, the pharmaceutical composition comprising:

[0016] i) an anti-human CD39 antibody, the anti-human CD39 antibody comprising an antibody, the antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0017] a) a VHCDR1 having the sequence shown in SEQ ID NO: 1,

[0018] b) a VHCDR2 having the sequence shown in SEQ ID NO: 5, and

[0019] c) a VHCDR3 having the sequence shown in SEQ ID NO: 9,

[0020] And wherein the VL comprises or consists of:

[0021] a) VLCDR1 having the sequence shown in SEQ ID NO: 13,

[0022] b) VLCDR2 having the sequence shown in SEQ ID NO: 17, and

[0023] c) VLCDR3 having the sequence shown in SEQ ID NO: 21;

[0024] ii) an anti-human PD-1 antibody, comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0025] a) a VHCDR1 having the sequence shown in SEQ ID NO: 2,

[0026] b) a VHCDR2 having the sequence shown in SEQ ID NO: 6, and

[0027] c) a VHCDR3 having the sequence shown in SEQ ID NO: 10,

[0028] And wherein the VL comprises or consists of:

[0029] a) VLCDR1 having the sequence shown in SEQ ID NO: 14,

[0030] b) VLCDR2 having the sequence shown in SEQ ID NO: 18, and

[0031] b) VLCDR3 having the sequence shown in SEQ ID NO: 22; and

[0032] iii) FOLFOX or CAPOX.

[0033] The second aspect provides a pharmaceutical composition for treating a subject suffering from gastric cancer, the pharmaceutical composition comprising or consisting of:

[0034] i)i) an anti-human CD39 antibody, comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0035] a) a VHCDR1 having the sequence shown in SEQ ID NO: 1,

[0036] b) a VHCDR2 having the sequence shown in SEQ ID NO: 5, and

[0037] c) a VHCDR3 having the sequence shown in SEQ ID NO: 9,

[0038] And wherein the VL comprises or consists of:

[0039] a) VLCDR1 having the sequence shown in SEQ ID NO: 13,

[0040] b) VLCDR2 having the sequence shown in SEQ ID NO: 17, and

[0041] c) VLCDR3 having the sequence shown in SEQ ID NO: 21;

[0042] ii) an anti-human PD-1 antibody, comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0043] a) a VHCDR1 having the sequence shown in SEQ ID NO: 2,

[0044] b) a VHCDR2 having the sequence shown in SEQ ID NO: 6, and

[0045] c) a VHCDR3 having the sequence shown in SEQ ID NO: 10,

[0046] And wherein the VL comprises or consists of:

[0047] a) VLCDR1 having the sequence shown in SEQ ID NO: 14,

[0048] b) VLCDR2 having the sequence shown in SEQ ID NO: 18, and

[0049] b) VLCDR3 having the sequence shown in SEQ ID NO: 22; and

[0050] iii) FOLFOX or CAPOX.

[0051] In some embodiments, the anti-human CD39 antibody is administered at a dose of 0.5 mg / kg to 40.0 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 20.0 mg / kg.

[0052] In some embodiments, the anti-human PD-1 antibody is administered at a dose of 500 mg. In some embodiments, FOLFOX is administered with a component having a dose of: 85 mg / m 2 Oxaliplatin; 400 mg / m2 of folinic acid; and 400 mg / m 2 Bolus infusion and 2400 mg / m 2 Continuous infusion of 5-FU. In some embodiments, FOLFOX comprises mFOLFOX6.

[0053] In some embodiments, the gastric cancer includes locally advanced or metastatic gastric cancer. In some embodiments, the gastric cancer is Her2 - .

[0054] In some embodiments, the step of administering any of the antibodies or FOLFOX or CAPOX comprises intravenous administration. In some embodiments, the pharmaceutical composition may be administered intravenously.

[0055] In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 40.0 mg / kg. In some embodiments, one week after administration of the loading dose, the anti-human CD39 antibody is administered to the subject at a dose of 20.0 mg / kg every two weeks.

[0056] In some embodiments, the anti-human PD-1 antibody is administered to the subject at a dose of 500 mg every four weeks. In some embodiments, FOLFOX includes mFOLFOX6, and mFOLFOX6 is administered once every 2 weeks.

[0057] In some embodiments, the anti-human CD39 antibody is an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 25, and the light chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 29. In some embodiments, the anti-human CD39 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 33, and the light chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 34.

[0058] In some embodiments, the anti-human PD-1 antibody is an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 26, and the light chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 30. In some embodiments, the anti-human PD-1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 35 or SEQ ID NO: 36, and the light chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 37.

[0059] In some embodiments, the subject has a partial response or a complete response. In some embodiments, the method or the pharmaceutical composition produces an OS of 40%, 50%, 60%, 70% or 80%. In some embodiments, the method or the pharmaceutical composition increases PFS or DFS.

[0060] BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 CD39 monotherapy dose escalation and expansion are shown.

[0062] Figure 2 Eligibility and patient demographics and disease characteristics for treatment of metastatic gastroesophageal cancer with CD39 antibody, anti-PD-1 antibody (budigalimab), and FOLFOX are shown.

[0063] FIG. 3 shows patient responses following treatment of metastatic gastroesophageal cancer with CD39 antibody, brigatinib, and FOLFOX. Figure 3A A treatment duration swimming graph is shown, and Figure 3B Lanes divided according to CPS scores are shown.

[0064] Figure 4 The maximum changes from baseline for treatment of metastatic gastroesophageal cancer with CD39 antibody, brigatinib, and FOLFOX are shown.

[0065] Figure 5 Shown is the onset of tumor response in metastatic gastroesophageal cancer treated with CD39 antibody, brigatinib, and FOLFOX.

[0066] Figure 6 shows that combination treatment resulted in an increase in PD-L1 and CD8 T cells. Fig. 6A Combination treatment was shown to result in an increase in PD-L1 CPS score and CD8 T cells. Figure 6B Combination treatment was shown to result in an increase in CD8 cells. Figure 6C Combination therapy was shown to affect CD39 stromal therapy. DETAILED DESCRIPTION

[0067] 1. Definition

[0068] Unless otherwise defined, all technical terms, symbols and other scientific terms used herein are intended to have the meanings commonly understood by those skilled in the art to which the present invention belongs. In some cases, for clarity and / or for ease of reference, the terms with commonly understood meanings are defined herein, and such definitions are included herein and are not necessarily interpreted as indicating that the meanings commonly understood in the art have differences. The techniques and procedures described herein or cited are generally understood by those skilled in the art and are generally used to use conventional methods, for example, the widely used molecular cloning methods described below: Sambrook et al., "Molecular Cloning: A Laboratory Manual", 2nd edition, (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Where appropriate, unless otherwise noted, the procedures involving the use of commercially available kits and reagents are generally performed according to the schemes and / or parameters defined by the manufacturer.

[0069] The terms "CD39" and "CD39 antigen" and "cluster of differentiation 39" are used interchangeably herein. CD39 is also known as ectonucleoside triphosphate diphosphohydrolase-1 (gene: ENTPDJ; protein: NTPDase1, see www.ncbi.nlm.nih.gov / gene / 953). CD39 is also known as ATPDase and SPG64.

[0070] The terms "PD-1," "programmed cell death protein 1," and "cluster of differentiation 279" are used interchangeably herein.

[0071] As used herein, "FOLFOX" shall refer to a combination chemotherapy comprising leucovorin, fluorouracil, and oxaliplatin. There are several different FOLFOX regimens, including FOLFOX-4, FOLFOX-6, modified FOLFOX-6 (mFOLFOX-6), and FOLFOX-7. These regimens differ in the dosage and manner in which these three drugs are given.

[0072] As used herein, "CAPOX" refers to a combination chemotherapy comprising oxaliplatin and capecitabine. CAPOX may also be referred to as XELOX, CAPE-OX, and OxCap.

[0073] As used herein, "RP2D" refers to the recommended Phase 2 dose of one or more agents determined by dose-limiting toxicity. In oncology, it is defined as the dose level that produces approximately 20% dose-limiting toxicity. In North America, the maximum tolerated dose is the RP2D, while in other parts of the world, the MTD is considered to be a dose greater than the RP2D. Sponsors typically select the RPTD based on the safety, tolerability, efficacy, pharmacokinetic, and pharmacodynamic data collected during the dose escalation portion of the study in consultation with the investigators of the dose expansion group.

[0074] As used herein, "overall survival" or "OS" shall mean the time from diagnosis (or start of treatment) to death.

[0075] As used herein, "disease-free survival" or "DFS" or "recurrence-free survival" or "RFS" refers to the length of time a patient survives without any signs or symptoms of cancer after cancer treatment ends.

[0076] As used herein, "progression-free survival" or "PFS" refers to the time from the first day a participant receives the first dose of study treatment to the first day of disease progression or death, whichever occurs first.

[0077] “Duration of response” and “DOR” shall mean the time from the first documented disease response (CR or PR) to the first documented progression or death from any cause, whichever occurs first.

[0078] "Objective response rate" or "ORR" refers to the percentage of subjects with unconfirmed and confirmed CR or unconfirmed and confirmed PR.

[0079] A "complete response" or "CR" refers to the disappearance of all target lesions; any pathological lymph node (whether target or non-target lesion) must shrink to less than 10 mm in the short axis.

[0080] "Partial response" or "PR" means a reduction of at least 30% in the sum of the diameters of the target lesions; the reference is the baseline diameter.

[0081] As used herein, "stable disease" or "SD" refers to neither sufficient shrinkage compared to baseline to qualify as a partial response nor sufficient increase (referenced to the smallest summed diameter on study) to qualify as PD.

[0082] As used herein, "progressive disease" or "PD" shall mean an increase of at least 20% in the sum of diameters of target lesions, taking the smallest sum in the study as reference (including the baseline sum if this is the smallest sum in the study). In addition to the 20% relative increase, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

[0083] As used herein, "DCR," "Disease Control Rate," "CBR," and "Clinical Benefit Rate" shall refer to the percentage of patients with advanced or metastatic cancer who have achieved CR, PR, and SD.

[0084] As used herein, “CPS” shall mean the total number of PD-L1 stained cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells multiplied by 100.

[0085] As used herein, "BOR" or "Best Overall Response" shall refer to the single best response status at any assessment time point prior to receipt of non-protocol therapy or prior to PD.

[0086] As used herein, the term "subject" means a mammalian subject. In some embodiments, the subject is a human.

[0087] 2. Methods

[0088] Disclosed herein are combinations and dosing regimens and compositions combining CD39 antibodies, PD-1 antibodies, and FOLFOX or CAPOX.

[0089] A first aspect provides a method for treating a subject suffering from gastric cancer, the method comprising the step of administering to the subject a pharmaceutical composition, the pharmaceutical composition comprising:

[0090] i) an anti-human CD39 antibody, the anti-human CD39 antibody comprising an antibody, the antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0091] a) a VHCDR1 having the sequence shown in SEQ ID NO: 1,

[0092] b) a VHCDR2 having the sequence shown in SEQ ID NO: 5, and

[0093] c) a VHCDR3 having the sequence shown in SEQ ID NO: 9,

[0094] And wherein the VL comprises or consists of:

[0095] a) VLCDR1 having the sequence shown in SEQ ID NO: 13,

[0096] b) VLCDR2 having the sequence shown in SEQ ID NO: 17, and

[0097] c) VLCDR3 having the sequence shown in SEQ ID NO: 21;

[0098] ii) an anti-human PD-1 antibody, comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0099] a) a VHCDR1 having the sequence shown in SEQ ID NO: 2,

[0100] b) a VHCDR2 having the sequence shown in SEQ ID NO: 6, and

[0101] c) a VHCDR3 having the sequence shown in SEQ ID NO: 10,

[0102] And wherein the VL comprises or consists of:

[0103] a) VLCDR1 having the sequence shown in SEQ ID NO: 14,

[0104] b) VLCDR2 having the sequence shown in SEQ ID NO: 18, and

[0105] b) VLCDR3 having the sequence shown in SEQ ID NO: 22; and

[0106] iii) FOLFOX or CAPOX.

[0107] In some embodiments, the anti-human CD39 antibody is administered at a dose of 0.5 mg / kg to 40.0 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 20.0 mg / kg.

[0108] In some embodiments, the anti-human PD-1 antibody is administered at a dose of 500 mg. In some embodiments, FOLFOX is administered with a component having a dose of: 85 mg / m 2 Oxaliplatin; 400 mg / m 2 of folinic acid; and 400 mg / m 2 Bolus infusion and 2400 mg / m 2Continuous infusion of 5-FU. In some embodiments, FOLFOX comprises mFOLFOX6.

[0109] In some embodiments, the gastric cancer includes locally advanced or metastatic gastric cancer. In some embodiments, the gastric cancer is Her2 - .

[0110] In some embodiments, the step of administering any of the antibodies and / or FOLFOX or CAPOX comprises intravenous administration. In some embodiments, the pharmaceutical composition may be administered intravenously.

[0111] In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 40.0 mg / kg. In some embodiments, one week after administration of the loading dose, the anti-human CD39 antibody is administered to the subject at a dose of 20.0 mg / kg every two weeks.

[0112] In some embodiments, the anti-human PD-1 antibody is administered to the subject at a dose of 500 mg every four weeks. In some embodiments, FOLFOX includes mFOLFOX6, and mFOLFOX6 is administered once every 2 weeks.

[0113] In some embodiments, the anti-human CD39 antibody is an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 25, and the light chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 29. In some embodiments, the anti-human CD39 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 33, and the light chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 34.

[0114] In some embodiments, the anti-human PD-1 antibody is a brigatinib comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 26, and the light chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 30. In some embodiments, brigatinib comprises a heavy chain and a light chain, the heavy chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 35 or SEQ ID NO: 36, and the light chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 37.

[0115] Other anti-human PD-1 antibodies can be used. For example, in some embodiments, the anti-human PD-1 antibody is nivolumab and comprises or consists of an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0116] a) a VHCDR1 having the sequence shown in SEQ ID NO: 3,

[0117] b) a VHCDR2 having the sequence shown in SEQ ID NO: 7, and

[0118] c) a VHCDR3 having the sequence shown in SEQ ID NO: 11,

[0119] And wherein the VL comprises or consists of:

[0120] a) VLCDR1 having the sequence shown in SEQ ID NO: 15,

[0121] b) VLCDR2 having the sequence shown in SEQ ID NO: 19, and

[0122] c) VLCDR3 having the sequence shown in SEQ ID NO:23.

[0123] In some embodiments, the anti-human PD-1 antibody is an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 27, and the light chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 31. In some embodiments, the anti-human PD-1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 38, and the light chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 39.

[0124] In some embodiments, the anti-human PD-1 antibody is pembrolizamab and comprises or consists of an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0125] a) a VHCDR1 having the sequence shown in SEQ ID NO: 4,

[0126] b) a VHCDR2 having the sequence shown in SEQ ID NO: 8, and

[0127] c) a VHCDR3 having the sequence shown in SEQ ID NO: 12,

[0128] And wherein the VL comprises or consists of:

[0129] a) VLCDR1 having the sequence shown in SEQ ID NO: 16,

[0130] b) VLCDR2 having the sequence shown in SEQ ID NO: 20, and

[0131] c) VLCDR3 having the sequence shown in SEQ ID NO:24.

[0132] In some embodiments, the anti-human PD-1 antibody is an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 28, and the light chain variable region comprising or consisting of a molecule having a sequence comprising or consisting of SEQ ID NO: 32. In some embodiments, the anti-human PD-1 antibody is an antibody comprising a heavy chain and a light chain, the heavy chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 40, and the light chain comprising or consisting of one or more molecules having a sequence comprising or consisting of SEQ ID NO: 41.

[0133] 3. Pharmaceutical Composition

[0134] The second aspect provides a pharmaceutical composition for treating a subject suffering from gastric cancer, the pharmaceutical composition comprising or consisting of:

[0135] i) an anti-human CD39 antibody, the anti-human CD39 antibody comprising an antibody, the antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0136] a) a VHCDR1 having the sequence shown in SEQ ID NO: 1,

[0137] b) a VHCDR2 having the sequence shown in SEQ ID NO: 5, and

[0138] c) a VHCDR3 having the sequence shown in SEQ ID NO: 9,

[0139] And wherein the VL comprises or consists of:

[0140] a) VLCDR1 having the sequence shown in SEQ ID NO: 13,

[0141] b) VLCDR2 having the sequence shown in SEQ ID NO: 17, and

[0142] c) VLCDR3 having the sequence shown in SEQ ID NO: 21;

[0143] ii) an anti-human PD-1 antibody, comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises or consists of:

[0144] a) a VHCDR1 having the sequence shown in SEQ ID NO: 2,

[0145] b) a VHCDR2 having the sequence shown in SEQ ID NO: 6, and

[0146] c) a VHCDR3 having the sequence shown in SEQ ID NO: 10,

[0147] And wherein the VL comprises or consists of:

[0148] a) VLCDR1 having the sequence shown in SEQ ID NO: 14,

[0149] b) VLCDR2 having the sequence shown in SEQ ID NO: 18, and

[0150] b) VLCDR3 having the sequence shown in SEQ ID NO: 22; and

[0151] iii) FOLFOX or CAPOX.

[0152] The pharmaceutical composition for each of the corresponding antibody and FOLFOX or CAPOX will contain one or more active agents, and may further contain solvents, buffers, diluents, carriers and other excipients to assist in the administration, solubility, absorption or bioavailability and / or stability of the active agent or the overall composition. Each of the antibody and FOLFOX or CAPOX can be provided in an appropriate pharmaceutical composition and administered by any suitable route of administration. The routes of administration suitable for each of the antibody and FOLFOX or CAPOX include but are not limited to inhalation, intra-arterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary and subcutaneous routes. Each composition may include one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and a person of ordinary skill in the art will be able to select a suitable pharmaceutical excipient. Additional pharmaceutical excipients include, for example, pharmaceutical excipients described in Handbook of Pharmaceutical Excipients, Rowe et al. (eds.) 6th edition (2009), which is incorporated by reference in its entirety.

[0153] 4. Dosage form

[0154] The physician will determine what she deems the most appropriate posology based on the age, weight, condition of the subject to be treated and other factors specific to the subject, including available guidance on recommended dosages.

[0155] In some embodiments, the anti-human CD39 antibody is administered at a dose of 0.5 mg / kg to 60 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 0.5 mg / kg to 1 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 1 mg / kg to 5 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 5 mg / kg to 10 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 10 mg / kg to 15 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 15 mg / kg to 20 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 20 mg / kg to 25 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 25 mg / kg to 30 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 30 mg / kg to 35 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 35 mg / kg to 40 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 40 mg / kg to 45 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 45 mg / kg to 50 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 50 mg / kg to 55 mg / kg. In some embodiments, the anti-human CD39 antibody is administered at a dose of 55 mg / kg to 60 mg / kg.

[0156] In some embodiments, the anti-human CD39 antibody is administered at a dose of 30 mg / kg Q3W or a dose of 20 mg / kg Q2W.

[0157] In some embodiments, the anti-human PD-1 antibody is administered at a dose of 1 mg to 1 g. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 50 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 100 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 150 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 200 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 250 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 300 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 350 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 400 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 450 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 500 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 550 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 600 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 650 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 700 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 750 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 800 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 850 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 900 mg. In some embodiments, the anti-human PD-1 antibody is administered at a dose of 950 mg.

[0158] In some embodiments, the anti-human PD-1 antibody is administered at a fixed dose of 275 mg Q2W, a fixed dose of 375 mg Q3W, or a fixed dose of 500 mg Q4W.

[0159] In some embodiments, treatment or prevention can be started with one or more loading doses of the antibody or composition provided herein, followed by one or more maintenance doses. In some embodiments, the one or more loading doses include one or more loading doses of the anti-human CD39 antibody. In some embodiments, the one or more loading doses are administered at a dose between 5 mg / kg and 100 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 5.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 10.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 15.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 20.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 25.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 30.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 35.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 40.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 45.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 50.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 55.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 60.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 65.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 70.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 75.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 80.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 85.0 mg / kg.In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 90.0 mg / kg. In some embodiments, a single loading dose of the anti-human CD39 antibody is administered to the subject at a dose of 95.0 mg / kg.

[0160] In some embodiments, FOLFOX is administered with a component having a dosage of: 85 mg / m 2 Oxaliplatin; 400 mg / m 2 of folinic acid; and 400 mg / m 2 Bolus infusion and 2400 mg / m 2 Continuous infusion of 5-FU. In some embodiments, FOLFOX comprises mFOLFOX6.

[0161] In certain embodiments, a certain dose of antibody or compositions provided herein can be administered to achieve a steady-state concentration of the antibody in the blood or serum of a subject. Steady-state concentration can be determined by measuring according to the available technology of those skilled in the art, or can be based on the physical characteristics of the subject, such as height, weight and age.

[0162] 5. Schedule

[0163] Frequency and dosage will also vary according to factors specific to each subject, depending on the specific therapy being administered and the subject's age, weight, response, and previous medical history. In addition, it should be noted that the clinician or attending physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with the subject's response.

[0164] In some embodiments, the combination is assembled in vivo in the subject being treated, whether they are administered at the same time or at different times. In some embodiments, the components of the combination are mixed together at the point of care prior to administration.

[0165] In some embodiments, the CD39 antibody, PD-1 antibody, and FOLFOX or CAPOX are administered on the same schedule. In some embodiments, the CD39 antibody, PD-1 antibody, and FOLFOX or CAPOX are administered on different schedules. In some embodiments, the CD39 antibody and PD-1 antibody are administered on the same schedule, but the FOLFOX or CAPOX is administered on a different schedule.

[0166] In some embodiments, the CD39 antibody is administered once a week. In some embodiments, the CD39 antibody is administered once every other week. In some embodiments, the CD39 antibody is administered once every three weeks. In some embodiments, the CD39 antibody is administered once every four weeks. In some embodiments, the CD39 antibody is administered once every five weeks. In some embodiments, the CD39 antibody is administered once every six weeks. In some embodiments, the CD39 antibody is administered once every seven weeks. In some embodiments, the CD39 antibody is administered once every eight weeks.

[0167] In some embodiments, the dosage and administration frequency of the CD39 antibody is 20 mg / kg every two weeks. In some embodiments, the dosage and administration frequency of the CD39 antibody is 30 mg / kg every three weeks. In some embodiments, the dosage and administration frequency of the CD39 antibody is 40 mg / kg every four weeks.

[0168] In some embodiments, the PD-1 antibody is administered once a week. In some embodiments, the PD-1 antibody is administered once every other week. In some embodiments, the PD-1 antibody is administered once every three weeks. In some embodiments, the PD-1 antibody is administered once every four weeks. In some embodiments, the CD39 antibody is administered once every five weeks. In some embodiments, the PD-1 antibody is administered once every six weeks. In some embodiments, the PD-1 antibody is administered once every seven weeks. In some embodiments, the PD-1 antibody is administered once every eight weeks.

[0169] In some embodiments, the dosage and administration frequency of the PD-1 antibody is 100 mg to 300 mg per week. In some embodiments, the dosage and administration frequency of the PD-1 antibody is 200 mg to 400 mg every two weeks. In some embodiments, the dosage and administration frequency of the PD-1 antibody is 300 mg and 500 mg every three weeks. In some embodiments, the dosage and administration frequency of the PD-1 antibody is 400 mg and 600 mg every four weeks. In some embodiments, the dosage and administration frequency of the PD-1 antibody is 500 mg and 700 mg every five weeks. In some embodiments, the dosage and administration frequency of the PD-1 antibody is 600 mg and 800 mg every six weeks. In some embodiments, the dosage and administration frequency of the PD-1 antibody is 700 mg and 900 mg every seven weeks. In some embodiments, the dosage and administration frequency of the PD-1 antibody is 800 mg and 1 g every eight weeks.

[0170] In some embodiments, the anti-human CD39 antibody is administered on days 1 and 15 of a 28-day cycle. In some embodiments, the anti-human PD1 antibody is administered to the subject at a dose of 500 mg every four weeks. In some embodiments, mFOLFOX6 is administered on days 1 and 15 of a 28-day cycle.

[0171] In some embodiments, the dosing regimen further comprises an initial loading dose of 40 mg / kg one week prior to starting the repeating portion of the dosing regimen (the maintenance dose).

[0172] In some embodiments, the dosing regimen further includes an initial loading dose between 10 mg / kg and 90 mg / kg. In some embodiments, the loading dose is 10 mg / kg. In some embodiments, the loading dose is 20 mg / kg. In some embodiments, the loading dose is 30 mg / kg. In some embodiments, the loading dose is 40 mg / kg. In some embodiments, the loading dose is 50 mg / kg. In some embodiments, the loading dose is 60 mg / kg. In some embodiments, the loading dose is 70 mg / kg. In some embodiments, the loading dose is 80 mg / kg. In some embodiments, the loading dose is 90 mg / kg.

[0173] These dosage regimens are generally sufficient to maintain the trough concentration of anti-human CD39 antibodies at 50 μg / ml or more. By adjusting the dosage accordingly, other trough concentrations can be achieved. These specific regimens provide the benefit of relatively convenient outpatient treatment, but other dosage regimens involving more frequently administered smaller doses can also be used, until and including continuous intravenous infusion (IV drip). Any of these dosage regimens can be referred to as maintaining the serum trough concentration of CD39 binding proteins at a threshold level or above the threshold level or a step, or maintaining the threshold level or above the threshold level in 85% of the subjects. In some embodiments, the threshold level is 10 μg / mL, 20 μg / mL, 30 μg / mL, 40 μg / mL, 50 μg / mL or 60 μg / mL.

[0174] 6. RECIST and Response

[0175] The assessment of tumor burden is an important criterion for evaluation. Any method can be used to assess response. Some embodiments provide using RECIST criteria to assess response (see, https: / / recist.eortc.org / recist-1-1-2 / and new response assessment criteria in solid tumors: revised RECIST guidelines (version 1.1), "European Journal of Cancer (European Journal of Cancer)" 45 (2009) 228-247, the document is incorporated by reference in its entirety).

[0176] In order to demonstrate efficacy, the objective response rate of the subject treated with the method or composition should be greater than 25% or greater than 30%. In some embodiments, the median DOR of the efficacy of the treatment is 6 months or longer (i.e., at least 6 months, at least 8 months and / or at least 10 months). Other efficacy endpoints include PFS, OS and / or acceptable safety and tolerability characteristics.

[0177] In some embodiments, the method or pharmaceutical composition provides a partial response or a complete response. In some embodiments, the method or pharmaceutical composition produces 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% OS. In some embodiments, the method or pharmaceutical composition increases PFS or DFS.

[0178] Different methods can be used to measure tumors. Some internal cancer tumors will show up on an x-ray or CT scan and can be measured with a ruler. Blood tests may be done, including blood tests that measure organ function. Tumor marker tests may be done for some cancers.

[0179] Whatever test is used, whether it is a blood test, a cell count, or a tumor marker test, it is repeated at specific intervals so that the results can be compared with an earlier test of the same type.

[0180] Other measures of efficacy of cancer treatments include overall survival interval (i.e., time to death from any cause measured from diagnosis or from the start of the treatment being evaluated), cancer-free survival (i.e., the length of time that cancer remains undetectable after a complete response), and progression-free survival (i.e., the length of time that resumption of tumor growth is undetectable after stable disease or a partial response).

[0181] In some embodiments, an increase in treatment-induced CPS scores can be seen. The CPS score at baseline may be associated with responsiveness to a treatment regimen containing an anti-PD-1 or anti-PD-L1 agent. More specifically, when combined with chemotherapy for gastric cancer as exemplified herein, the CPS score may be associated with improvements in ORR, PFS, or OS.

[0182] In some embodiments, the subject has a CPS score. In some embodiments, the CPS score is less than 1. In some embodiments, the CPS score is greater than or equal to 1 and less than 5. In some embodiments, the CPS is greater than or equal to 5.

[0183] In some embodiments, treatment induces an increase in the CPS score. Changes in the CPS score can reflect an increase in anti-tumor immune activity and may be associated with clinical response. Changes in the CPS can predict clinical response before radiological assessment.

[0184] In some embodiments, the treatment induces an increase in CD8 cells. CD8 T cells are known to mediate anti-tumor immunity, and an increase in CD8 T cells may be associated with clinical response.

[0185] In some embodiments, the treatment induces an increase in CD39 along with an increase in CD8 T cells. It is known that expression of CD39 on CD8 T cells enriches for tumor-reactive T cells, distinguishing them from bystander T cells.

[0186] Table S sequence.

[0187]

[0188]

[0189]

[0190]

[0191]

[0192] Example Example 1: Inclusions and Exclusions and Dose Identification

[0193] Inclusion criteria included male or female subjects aged ≥18 years at screening (or for Korea: ≥19 years at screening), fresh and / or archived tumor tissue, body weight ≥35 kg, evidence of measurable disease by computed tomography (CT), CT-positron emission tomography (PET), or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, life expectancy >12 weeks, and Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

[0194] Inclusion criteria also included adequate organ and bone marrow function, defined as:

[0195] a. Absolute neutrophil count ≥1.5k / μL, platelets ≥75k / μL (for the chemotherapy group, platelets ≥100k / gL), hemoglobin ≥8g / dL (for the chemotherapy group, hemoglobin ≥9g / dL).

[0196] b. Serum creatinine ≤ 1.5x upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 40 mL / min. Please note: Subjects eligible for Cohort 10 may have a CrCl < 40 mL / min with approval by the medical supervisor.

[0197] c. Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤2.5x ULN (or ≤5x ULN with liver transferase).

[0198] d. Total bilirubin ≤2x ULN (or ≤3x ULN with Gilbert's syndrome).

[0199] e. Prothrombin time (PT) / international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.2x ULN; fibrinogen ≥ 150 mg / dL.

[0200] f. Serum albumin ≥3.0 g / dL.

[0201] Subjects must also have received at least 14 days after the last dose of chemotherapy or biological therapy or tyrosine kinase inhibitor or high-dose (e.g., >10 mg prednisone or equivalent per day) steroid therapy prior to the loading dose / first dose of study treatment, or received other second-generation hormone therapy prior to the loading dose / first dose of study treatment. It is also required that any adverse reactions to previous chemotherapy, immunotherapy, or previous systemic anticancer therapy, radiation therapy, or surgery be eliminated to Grade 1 or baseline (except Grade 2 alopecia and Grade 2 sensory neuropathy). Subjects with a history of congestive heart failure are required to have a cardiac echocardiogram or multi-gated acquisition scan within 21 days prior to the loading dose / first dose of study treatment, indicating a left ventricular ejection fraction ≥45%.

[0202] Inclusion criteria also included histologically or cytologically confirmed advanced unresectable or metastatic adenocarcinoma of the stomach or gastroesophageal junction with HER2-negative disease (HER2 0 or 1 by IHC, or HER2 2+ by IHC, and no HER2 gene amplification detected by in situ hybridization [ISH]). Subjects must have histologically or cytologically confirmed HER2-negative disease (HER2 0 or 1 by IHC, or HER2 2+ by IHC, and no HER2 gene amplification detected by ISH) in the primary or metastatic tumor. No prior treatment for metastatic disease or prior (neo)adjuvant therapy within 6 months of study entry was required.

[0203] Exclusion criteria included a history of allergy or hypersensitivity to components of the study treatment. Subjects with a history of severe hypersensitivity reactions (defined as any grade 3 reaction lasting ≥48 hours despite optimal therapy) to any monoclonal antibody were excluded. Subjects who used study medication within fourteen (14) days prior to the loading dose / first dose of study treatment and throughout the study, and subjects who received chemotherapy, radiation therapy, biological therapy, herbal therapy, or any study therapy within 14 days prior to the loading dose / first dose of study treatment were excluded. Palliative radiation therapy for non-target lesions was permitted.

[0204] Subjects who received high-dose (e.g., >10 mg prednisone or equivalent per day) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the loading dose / first dose of study treatment were excluded; however, inhaled, intranasal, intraocular, topical, and intraarticular steroids were allowed. Brief steroid administration as an antiemetic or chemotherapy pretreatment (e.g., paclitaxel) was also allowed. Subjects receiving therapeutic anticoagulation were excluded. Prophylactic anticoagulation with low molecular weight heparin, factor Xa inhibitors, and low-dose aspirin was allowed. Patients with a history of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease) requiring systemic treatment or transplantation requiring systemic steroids or immunosuppressants within the past 2 years were excluded. Patients with a history of vitiligo, autoimmune thyroiditis, or mild psoriasis were allowed.

[0205] Subjects with a known history of HIV or other chronic immunodeficiency were excluded. In addition, subjects with uncontrolled concurrent illnesses were excluded, including but not limited to:

[0206] - Uncontrolled diabetes.

[0207] -Persistent or active bacterial, viral, or fungal infection requiring systemic therapy.

[0208] - Clinically significant congestive heart failure as defined by New York Heart Association class 3 or 4.

[0209] - Unstable angina, arrhythmia, or myocardial infarction within 6 months prior to screening.

[0210] - Uncontrolled tumor-related pain. (Subjects requiring narcotic pain medication must be on a stable regimen at study entry).

[0211] - Poorly controlled hypertension, defined as blood pressure consistently above 150 / 90 mmHg despite optimal medical management.

[0212] -Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters (eg, ).

[0213] - Active or chronic viral hepatitis B or C infection. Subjects who tested positive for hepatitis B surface antigen or hepatitis C antibody were excluded. If hepatitis B core antibody was positive, the subject must have a negative PCR result prior to enrollment. Subjects with a positive PCR were excluded.

[0214] -Uncontrolled thyroid disease.

[0215] - Known history of active pulmonary tuberculosis.

[0216] - Active infection requiring systemic therapy (≥Grade 2) for more than 3 days within 1 week of dosing.

[0217] Subjects with active or untreated central nervous system metastases are excluded. Subjects with brain metastases are eligible if the subject can show clinical and radiographic SD within at least 4 weeks after definitive therapy and steroids (>10mg / day of prednisone or equivalent) were not used within at least 4 weeks before loading dose / first dose of study treatment. Subjects with any other malignant tumor history in the past 3 years are excluded (except for non-melanoma skin cancer or limited carcinoma in situ that the investigator believes has been cured or fully treated successfully). Subjects with completely resected skin melanoma (early stage), basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, and limited prostate cancer are eligible.

[0218] Pregnant or lactating women were excluded. Subjects who received a live vaccine within 28 days before the loading dose / first dose of study drug were excluded. Subjects with a history of pneumonia or interstitial lung disease (except in the setting of PD-(L)1 therapy) or persistence and with a history of idiopathic pulmonary fibrosis, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonia, or idiopathic pneumonia were excluded. Subjects who had been previously treated with an anti-PD-(L)1 targeted agent were excluded if they developed any of the following during the course of therapy:

[0219] a. Any immune-mediated toxicity of Grade 3 or higher severity.

[0220] b. Any ocular or neurological toxicity.

[0221] c. Any hypersensitivity reaction to PD-(L)1-targeted agents in subjects in the cohorts containing brigatinib and pembrolizumab.

[0222] Subjects with evidence of persistent hemolysis on the hemolysis panel (total bilirubin, direct bilirubin, and unconjugated serum bilirubin, peripheral blood smear, D-dimer, and serum haptoglobin) as judged by the investigator were excluded. Subjects who had undergone major surgery according to the investigator within 28 days before the loading dose / first dose of study drug and whose surgical wound was not fully healed were excluded. Diagnostic or research biopsies did not exclude subjects from enrollment, and the placement of a vascular access device (such as Port-A-Cath) was not considered a major surgical procedure. Subjects with a history of major immune reaction (grade 3-4) to any IgG-containing agent were excluded. Subjects with a history of primary immunodeficiency, bone marrow transplant, chronic lymphocytic leukemia, solid organ transplant, or previous clinical diagnosis of tuberculosis were excluded. Subjects with a history of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS) were excluded.

[0223] Exclusion criteria also included inability to receive a trans-port or peripherally inserted central catheter, known hypersensitivity to 5-FU, oxaliplatin or other platinum agents, known hypersensitivity to mFOLFOX6 or any of its excipients, known dihydropyrimidine dehydrogenase deficiency (testing not required), and baseline peripheral neuropathy / paresthesia grade >1.

[0224] Six subjects with various advanced solid tumors received the following combination regimens:

[0225] - Anti-human CD39 antibody (40 mg / kg 7 days prior to Cycle 1 Day 1, followed by 20 mg / kg Q2W).

[0226] -Buglilimab (500 mg every 4 weeks [Q4W]).

[0227] -mFOLFOX6 (oxaliplatin 85 mg / m within 2 hours 2 IV and leucovorin 400 mg / m 2 IV plus 5-FU 400 mg / m within 46 hours 2 IV bolus and 2400 mg / m 2 continuous infusion, Q2W).

[0228] Example 2: Combination of anti-human CD39 antibody and anti-human PD-1 antibody in subjects with advanced gastroesophageal cancer Chemotherapy

[0229] Figure 1 Shown are monotherapy dose escalation and expansion and study designs for the treatment of metastatic gastroesophageal cancer with CD39 antibody, PD-1 antibody (Buglimab), and FOLFOX. Figure 2 Eligibility and patient demographics and disease characteristics for treatment of metastatic gastroesophageal cancer with CD39 antibody, brigatinib, and FOLFOX are shown.

[0230] 70 response-evaluable subjects with human epidermal growth factor receptor 2 (HER2)-negative metastatic gastroesophageal cancer (GEC) were administered the doses set forth below.

[0231] 1. Group A: anti-human CD39 antibody + mFOLFOX6 (n=6).

[0232] 2. Cohort 3 Group B: anti-human CD39 antibody + brigatinib + mFOLFOX6 (n=40).

[0233] 3. Briglimab + mFOLFOX6 (n = 24).

[0234] Inclusion criteria included histologically or cytologically confirmed advanced unresectable or metastatic adenocarcinoma of the stomach or gastroesophageal junction with HER2-negative disease (HER2 0 or 1 by IHC, or HER2 2+ by IHC, and no HER2 gene amplification detected by in situ hybridization [ISH]). Subjects were required to have histologically or cytologically confirmed HER2-negative disease (HER2 0 or 1 by IHC, or HER2 2+ by IHC, and no HER2 gene amplification detected by ISH) on the primary or metastatic tumor. Subjects were also required to have no prior treatment for metastatic disease within 6 months of study entry and no prior (neo)adjuvant therapy was required.

[0235] The RP2D of the anti-human CD39 antibody was determined to be a 40 mg / kg loading dose 7 days prior to Cycle 1 Day 1, followed by 30 mg / kg Q3W or 20 mg / kg Q2W. As shown below, doses up to 40 mg / kg were determined to be well tolerated.

[0236] PK showed that based on the activity of anti-human CD39 antibodies in preclinical human functional assays (i.e., enhancement of IL-2 from PBMCs and inflammasome activation), a dose of 40 mg / kg Q3W achieved the lowest functional trough level. The half-life was 18.9 days. After completing the dose escalation portion of the study, all PK data were used for PK modeling of RP2D. Based on simulation, it was determined that a loading dose of 40 mg / kg one week before administration of 30 mg / kg Q3W or 20 mg / kg Q2W on Day 1 of Cycle 1 would provide the lowest functional trough level in greater than 80% of subjects in the cycle before and after Day 1 of Cycle 1.

[0237] Based on the observed safety, PK, pharmacodynamics and efficacy data, the RP2D of the anti-human PD-1 antibody was determined to be a fixed dose of 250 mg Q2W, 375 mg Q3W or 500 mg Q4W. The RP2D was also supported by population PK modeling and simulations, which showed that the exposure achieved with a dose of 250 mg Q2W, 375 mg Q3W or 500 mg Q4W would result in saturation of PD-1-positive CD4 central memory T cells and significant PD-L1 blockade without further impact on safety.

[0238] mFOLFOX6 (oxaliplatin 85 mg / m within 2 hours) was administered based on standard clinical practice 2 IV and leucovorin 400 mg / m 2 IV plus 5-FU 400 mg / m within 46 hours 2 IV bolus and 2400 mg / m 2 Continuous infusion, Q2W administration). Changes to mFOLFOX6 (i.e., dose reduction or combination modification) may be permitted per institutional guidelines.

[0239] During, for example, a 28-day cycle, the anti-human CD39 antibody and the anti-human PD-1 antibody are administered within at least 60 minutes. mFOLFOX6 is administered within 48 hours.

[0240] FIG. 3 shows patient responses in metastatic gastroesophageal cancer treated with CD39 antibody, brigatinib, and FOLFOX. Figure 3A A treatment duration swimming graph is shown, and Figure 3B Lanes divided according to CPS scores are shown.

[0241] Figure 4 Shown are the maximum changes from baseline for treatment of metastatic gastroesophageal cancer with CD39 antibody, brigatinib, and FOLFOX, and waterfall plots according to CPS scores. Figure 4 Tumor responses across different PD-L1 levels at baseline are shown.

[0242] The BOR (RECIST) criteria for the total evaluable population N=40 are shown in Table 1 .

[0243] Table 1

[0244] BOR(RECIST)

[0245] Total evaluable population N = 40 [n (%)]

[0246]

[0247] Table 2 shows the ORR (RECIST) criteria for the subpopulation N=37 with known CPS.

[0248] Table 2

[0249] ORR (RECIST)

[0250] Subgroup with known CPS N = 37 [n (%)]

[0251]

[0252] Figure 5 Shown is the onset of tumor response in metastatic gastroesophageal cancer treated with CD39 antibody, brigatinib, and FOLFOX.

[0253] Figure 6 shows that combination treatment resulted in an increase in PD-L1 and CD8 T cells. Fig. 6A Combination treatment was shown to result in an increase in PD-L1 CPS score and CD8 T cells. Figure 6B Combination treatment was shown to result in an increase in CD8 cells. Figure 6C Combination therapy was shown to affect CD39 stromal therapy.

[0254] Unless otherwise indicated herein or clearly contradictory to the context, the terms "a", "an", "the" and similar references used in the context of describing the present invention (particularly in the context of the appended claims) should be interpreted as covering both the singular and the plural. Unless otherwise indicated herein or clearly contradictory to the context in other ways, all methods described herein can be performed in any suitable order. The use of any and all embodiments or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present invention and is not intended to limit the scope of the present invention to which protection is otherwise claimed. Any language in this specification should not be interpreted as indicating that any unclaimed element is necessary for practicing the present invention.

[0255] The specific embodiments disclosed herein may be further limited in the claims using consisting of or consisting essentially of language. When used in a claim, whether as filed or added by amendment, the transitional term "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of the claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics. The embodiments of the invention so claimed are inherently or expressly described and enabled herein.

[0256] All patents, patent publications and other publications cited and identified in this specification are individually and explicitly incorporated herein by reference in their entirety, for the purpose of describing and disclosing the compositions and methods that may be used in conjunction with the present invention, such as described in such publications. These publications are provided only for their disclosure before the filing date of the present application. Anything in this regard should not be construed as admitting that the inventor has no right to precede these disclosures due to previous inventions or for any other reason. All statements about the dates or contents of these documents are based on information available to the applicant and do not constitute any recognition of the correctness of the dates or contents of these documents.

Claims

1. A method for treating a subject suffering from gastric cancer, the method comprising the step of administering to the subject a pharmaceutical composition comprising: i) an anti-human CD39 antibody, wherein the anti-human CD39 antibody consists of a heavy chain amino acid of SEQ ID NO: 33 and a light chain amino acid of SEQ ID NO: 34; ii) an anti-human PD-1 antibody consisting of a heavy chain amino acid of SEQ ID NO: 35 and a light chain amino acid of SEQ ID NO: 36; and iii) mFOLFOX6, which consists of oxaliplatin, leucovorin and fluorouracil (5FU).

2. The method of claim 1, wherein the anti-human CD39 antibody is administered intravenously at a dose of 0.5 mg / kg to 40.0 mg / kg.

3. The method of claim 2, wherein the anti-human CD39 antibody is administered intravenously at a dose of 20.0 mg / kg.

4. The method of claim 1, wherein the anti-human PD-1 antibody is administered intravenously at a dose of 500 mg.

5. The method of claim 1, wherein mFOLFOX6 is administered intravenously in an amount of: 85 mg / m 2 Oxaliplatin; 400 mg / m 2 of folinic acid; and 400 mg / m 2 Bolus infusion and 2400 mg / m 2 Continuous infusion of 5-FU. The method of claim 1 , wherein the gastric cancer comprises locally advanced or metastatic gastric cancer.

7. The method of claim 6, wherein the gastric cancer is advanced unresectable or metastatic Her-2 - Adenocarcinoma.

8. The method of claim 1, wherein the anti-human CD39 antibody is administered on days 1 and 15 of a 28-day cycle.

9. The method of claim 1, wherein the mFOLFOX6 is administered on days 1 and 15 of a 28-day cycle.

10. The method of claim 8, wherein a single loading dose of the anti-human CD39 antibody at a dose of 40.0 mg / kg is administered to the subject one week prior to starting the repeating portion of the dosing regimen (maintenance dose).

11. The method of claim 1, wherein the anti-human PD1 antibody is administered to the subject at a dose of 500 mg every four weeks.

12. The method of claim 1, wherein the subject has a partial response or a complete response.

13. The method of claim 1, wherein the method results in an OS of 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90%.

14. The method of claim 1, wherein the method increases PFS or DFS.

15. A method for treating a subject having gastric cancer, the method comprising the step of administering to the subject a pharmaceutical composition comprising: i) an anti-human CD39 antibody, wherein the anti-human CD39 antibody consists of a heavy chain amino acid of SEQ ID NO: 33 and a light chain amino acid of SEQ ID NO: 34; ii) an anti-human PD-1 antibody consisting of a heavy chain amino acid of SEQ ID NO: 35 and a light chain amino acid of SEQ ID NO: 36; and iii) CAPOX.

16. The method of claim 15, wherein the anti-human CD39 antibody is administered intravenously at a dose of 0.5 mg / kg to 40.0 mg / kg.

17. The method of claim 16, wherein the anti-human CD39 antibody is administered intravenously at a dose of 20.0 mg / kg.

18. The method of claim 15, wherein the anti-human PD-1 antibody is administered intravenously at a dose of 500 mg.

19. The method of claim 15, wherein the gastric cancer comprises locally advanced or metastatic gastric cancer.

20. The method of claim 19, wherein the gastric cancer is advanced unresectable or metastatic Her-2 - Adenocarcinoma.

21. The method of claim 15, wherein the anti-human CD39 antibody is administered on days 1 and 15 of a 28-day cycle.

22. The method of claim 15, wherein the anti-human PD1 antibody is administered to the subject at a dose of 500 mg every four weeks.

23. The method of claim 15, wherein the subject has a partial response or a complete response.

24. The method of claim 15, wherein the method results in an OS of 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90%.

25. The method of claim 15, wherein the method increases PFS or DFS.

26. The method of any of the preceding claims, wherein the subject has a CPS score of less than 1, greater than or equal to 1 and less than 5, or greater than or equal to 5.

Citation Information

Cited By

  • Application of T-bet positive pTreg cell as drug target

    CN119925607A